ARTICLE | Clinical News

Inventiva and AbbVie discontinue development of RORgamma agonist

November 3, 2017 4:49 AM UTC

The partners also said they extended a deal to discover and develop a new oral RORgamma inverse agonist candidate. Inventiva will receive an undisclosed research payment and a milestone payment when a...